Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2017 / Aug / The (Dark) Art of Public Relations!

The (Dark) Art of Public Relations!

It takes work. But it’s more than worth it, when done intelligently.

By Mark Hillen 8/30/2017 1 min read

Share

For over a decade, I have spent the third Monday evening of each month in a local pub, where I run a SciBar. What is a SciBar? It gives local researchers the chance to present their work to the public; the scientists improve their communication skills, and the public gains a greater understanding of science. It’s great fun. At the last SciBar, four PhD students presented: How Much Do You Trust a Science Headline? The highlight was the paper in Nature Communications: Fenamate NSAIDs inhibit the NLRP inflammasome and protect against Alzheimer’s disease in rodent models (1), which turned into the headline: “Only 3p – the cost of the pill that could beat Alzheimer’s” in the Daily Mail. The research group was inundated by calls from the press asking for interviews and, more sadly, from patients and their families in search of what the press was implying was a cure. Then the conversation turned to science communication in general: how do you get people to understand your work – especially when it’s medical research – when the filter through the popular press distorts the message? I thought I’d share our ideas in the hope that some of you might find it useful.

Maximum result for minimum effort. Whether it’s explaining the inflammasome or promoting your premium IOL practice, focus your efforts on what will give you the maximum exposure to your target audience. And today, that still means the mainstream media (MSM). When you’re dealing with the MSM, there are three key ways to get your message across. First, you should write the article yourself; find the best possible angle, pitch it at the level of the intended audience, and send it as a press release to every journalist and TV news producer you can find. Journalists often have to write at least 10 articles a day – make it easy for them by doing it for them. Second, a picture paints a thousand words. If you have a print-quality, simple and clear graphic that illustrates your work, use it. If you don’t, make one. Place it on your website, and get it out with the press release. Third, take a leaf from the PR and communications agencies by writing what’s known as an ‘objection handler’ – essentially a well-thought FAQ page. Try to guess all of the questions that might be asked, list them, and provide the answers. These will all help reduce the chance of your work being misinterpreted and misreported – and increase the chance of your work (or what your practice can do) being reported as widely as possible. So, hijack the dark arts of PR, and use the inner workings of the MSM to educate to your advantage!

Mark Hillen
Editor

References

  1. MJ Daniels et al, “Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models ”, Nat Commun, 7, 12504 (2016). PMID: 27509875.

About the Author(s)

Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

More Articles by Mark Hillen

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: